AstraZeneca (AZN) Experiences Notable Market Shift: Key Insights

2 min read | September 20, 2024 08:02 PM PDT | By Team Kalkine Media

Headlines

  1. AstraZeneca (NASDAQ:AZN) closed at $78.38, down 0.66%, compared to a minor loss in the S&P 500.
  2. Over the past month, shares have decreased by 8.14%, trailing behind sector gains.
  3. Upcoming earnings are anticipated to show significant year-over-year growth in EPS and revenue.

The latest trading session for AstraZeneca (AZN) concluded with shares priced at $78.38, reflecting a decrease of 0.66% from the previous day's close. This decline was slightly less severe than the S&P 500's daily loss of 0.19%, while the Dow rose by 0.09% and the tech-heavy Nasdaq saw a drop of 0.36%.

In the past month, AstraZeneca's shares have experienced an 8.14% decline, which contrasts with the Medical sector's gain of 1.44% and the S&P 500's increase of 2.06%. Market participants are keenly awaiting the company’s upcoming financial results, with projected earnings per share (EPS) estimated at $1.07. This figure represents a 22.99% increase compared to the same quarter last year. Additionally, the latest consensus estimates predict revenue of $13.14 billion, reflecting a 14.37% rise from the prior-year quarter.

For the full year, analysts anticipate earnings of $4.05 per share and revenue of $52.48 billion, indicating year-over-year changes of 11.57% and 14.55%, respectively.

It is crucial to stay informed about recent changes in analyst projections for AstraZeneca, as these revisions often mirror current short-term business trends. Positive adjustments in estimates typically indicate optimism regarding the company's business outlook and profitability.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.


Sponsored Articles


Investing Ideas

Previous Next